OBALON THERPTCS (OBLN) Downgraded to “Sell” at Zacks Investment Research
Zacks Investment Research cut shares of OBALON THERPTCS (NASDAQ:OBLN) from a hold rating to a sell rating in a report issued on Wednesday morning.
According to Zacks, “Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company’s product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. “
Several other research analysts have also issued reports on the company. BTIG Research cut their price target on OBALON THERPTCS from $20.00 to $15.00 and set a buy rating on the stock in a report on Monday, November 6th. Northland Securities reiterated a sell rating and issued a $4.00 price target on shares of OBALON THERPTCS in a report on Friday, November 3rd. Finally, UBS AG reiterated a buy rating and issued a $20.00 price target (down previously from $22.00) on shares of OBALON THERPTCS in a report on Wednesday, August 9th. Three analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $13.00.
Shares of OBALON THERPTCS (OBLN) traded down $0.18 during trading hours on Wednesday, reaching $8.04. The company’s stock had a trading volume of 30,700 shares, compared to its average volume of 34,067. The company has a debt-to-equity ratio of 0.21, a quick ratio of 13.14 and a current ratio of 8.78. OBALON THERPTCS has a 1-year low of $7.77 and a 1-year high of $13.18.
OBALON THERPTCS (NASDAQ:OBLN) last announced its quarterly earnings results on Friday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.12). The firm had revenue of $2.79 million during the quarter, compared to the consensus estimate of $2.95 million. OBALON THERPTCS had a negative return on equity of 59.77% and a negative net margin of 459.54%. equities research analysts anticipate that OBALON THERPTCS will post -1.96 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/obalon-therptcs-obln-downgraded-to-sell-at-zacks-investment-research/1698335.html.
Institutional investors have recently modified their holdings of the company. UBS Group AG raised its stake in shares of OBALON THERPTCS by 90.8% in the first quarter. UBS Group AG now owns 11,856 shares of the company’s stock worth $127,000 after purchasing an additional 5,641 shares during the last quarter. Blair William & Co. IL purchased a new stake in shares of OBALON THERPTCS in the second quarter worth approximately $134,000. California State Teachers Retirement System raised its stake in shares of OBALON THERPTCS by 53.5% in the second quarter. California State Teachers Retirement System now owns 15,200 shares of the company’s stock worth $151,000 after purchasing an additional 5,300 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of OBALON THERPTCS in the first quarter worth approximately $168,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in shares of OBALON THERPTCS in the second quarter worth approximately $175,000. 44.73% of the stock is owned by hedge funds and other institutional investors.
OBALON THERPTCS Company Profile
Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OBALON THERPTCS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OBALON THERPTCS and related companies with Analyst Ratings Network's FREE daily email newsletter.